My Blue Dots

SALT LAKE CITY–(BUSINESS WIRE)–Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences. BTIG at Snowbird: The 12th Annual MedTech, Digital Health, LS&D Tools Conference in Salt Lake City, UT – Wednesday, February 12, 2025 (1×1 meetings only) B. Riley Securities Precision Oncology & Radiopharma Conference – Friday, February 28, 2025 in New York, NY (1×1 meetings only) About Varex Varex Imaging C

ATLANTA–(BUSINESS WIRE)–UPS (NYSE: UPS) today announced that it has completed the acquisition of Frigo-Trans and its sister company BPL, which provide industry-leading, complex healthcare logistics solutions across Europe. The acquisitions further enhance the end-to-end capabilities available to UPS Healthcare customers, who increasingly need temperature-controlled and time-critical logistics solutions globally. Frigo-Trans’ network includes temperature-controlled warehousing ranging from cry

SEATTLE–(BUSINESS WIRE)–Parse Biosciences, ein führender Anbieter von zugänglichen und skalierbaren Einzelzell-Sequenzierungslösungen, kündigte heute eine bedeutende Erweiterung der Funktionalität seines Evercode™ WT Mega Kit an. Forscher können nun bis zu 384 Proben und 1 Million Zellen in einem einzigen Durchlauf analysieren, was neue Möglichkeiten für Studien mit hohem Durchsatz eröffnet. Während sich die Einzelzelltechnologien stetig weiterentwickelt haben, stoßen viele immer noch an ihre

GLASGOW, Scotland–(BUSINESS WIRE)– #Chemify–Chemify hires biopharma veteran Dr. Alastair Leighton as Chief Operating Officer.

LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. “Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-o

PÉKIN et ALAMEDA, Californie et TAIPEI–(BUSINESS WIRE)–Biocytogen (HKEX : 02315) et Acepodia (6976 : TT) ont annoncé aujourd’hui un partenariat stratégique innovant visant à évaluer conjointement un programme de conjugué anticorps-médicament bispécifique (BsAD2C) à double charge. Cette collaboration associe la plateforme RenLite® de Biocytogen à la technologie Antibody-Dual-Drugs Conjugation (AD2C) d’Acepodia pour relever certains des défis les plus difficiles en oncologie : l’hétérogénéité d